Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

Saved in:

Bibliographic Details
Main Authors:	Judit Demeter, Julia Weisinger, Zsolt Nagy
Format:	Article
Language:	English
Published:	PAGEPress Publications 2021-02-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	chronic myeloid leukemia TKI COVID-19
Online Access:	https://www.mjhid.org/index.php/mjhid/article/view/4513
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Role of MicroRNAs in Chronic Myeloid Leukemia (CML) Treatment, Biomarkers, and Resistance to Tyrosine Kinase Inhibitor: A Bioinformatics-Based Analysis
by: Syarifah Faezah binti Syed Mohamad, et al.
Published: (2024-11-01)

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
by: Simona Bernardi, et al.
Published: (2019-05-01)

MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
by: Ibrahim C. Haznedaroglu
Published: (2013-12-01)

Dilemmas in the Diagnosis and Management of CML in Pakistan
by: Sahrish Khan, et al.
Published: (2024-12-01)

DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
by: Ibrahim C. Haznedaroglu
Published: (2015-02-01)

COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity
by: Na He, et al.
Published: (2024-11-01)

IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?
by: Federica Sorà, et al.
Published: (2021-10-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
by: Ivan Tonev, et al.
Published: (2025-01-01)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
by: Junichiro Yuda, et al.
Published: (2023-02-01)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection
by: Elisabetta Abruzzese, et al.
Published: (2020-04-01)

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

IFN‐α treatment may enable discontinuation of TKIs in NK cell‐licensed patients with CML‐CP
by: Hiroshi Ureshino, et al.
Published: (2024-12-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: Kotlyarchuk K., et al.
Published: (2015-09-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

6-month survival of patients with acute myeloid leukemia who received modified chemotherapy at Wahidin Sudirohusodo Hospital
by: Edwinda D. Ratu, et al.
Published: (2024-09-01)

Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: An in-silico approach
by: Uddalak Das, et al.
Published: (2025-06-01)

Chronic myeloid leukemia following nasopharyngeal carcinoma
by: olfa kassar
Published: (2014-08-01)

OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY
by: Mohamed Amine BEKADJA
Published: (2017-10-01)

Acute Myeloid Leukemia Presenting as a Cardiac Mass
by: Alia Magzoub Mohamed, et al.
Published: (2020-11-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA. A SINGLE CENTER TEN YEARS EXPERIENCE
by: Luana Fianchi, et al.
Published: (2021-04-01)

EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA. A SINGLE CENTER TEN YEARS EXPERIENCE
by: Luana Fianchi, et al.
Published: (2021-04-01)

COMPLETE REMISSION IN A PATIENT WITH CONCOMITANT DIAGNOSIS OF ACUTE MYELOID LEUKEMIA AND PULMONARY MUCORMICOSIS
by: saveria capria, et al.
Published: (2014-08-01)

Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment
by: Yi-gang Guo, et al.
Published: (2024-12-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Unraveling the unexpected: A rare case of filariasis in chronic myeloid leukemia with a review of the literature
by: Nikhil Kumar
Published: (2024-09-01)

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
by: Valentin Garcia-Gutierrez, et al.
Published: (2024-11-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01)

Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review
by: Domenico Santorsola, et al.
Published: (2015-02-01)

Delayed manifestation of proliferative retinopathy associated with chronic myeloid leukemia
by: Alan Chew Bonilla, et al.
Published: (2024-12-01)

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
by: Samuel Urrutia, et al.
Published: (2024-11-01)

Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
by: Mihee Kim, et al.
Published: (2024-12-01)

Expanding the therapeutic horizon in acute myeloid leukemia: The role of phosphoinositide-3-kinase-γ inhibition
by: Soumyajit Das, et al.
Published: (2024-12-01)

TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION
by: Elisabetta Abruzzese
Published: (2019-04-01)